Navigation Links
NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen
Date:11/12/2008

esults we announced last week for the 111 study. Both these ABPM trials suggest that naproxcinod's 24-hour blood pressure profile is improved compared to naproxen's and we are eager to receive the results of the ongoing 112 ABPM study in the coming months."

The 104 trial was an 8-week, double-blind, randomized, cross-over study, in which 131 hypertensive volunteers between 50 and 75 years of age were enrolled to receive either naproxcinod 750 mg bid for 2 weeks, followed by naproxen 500 mg bid for 2 weeks, or these compounds in the reverse order. Subjects received a 2-week placebo wash-out at the beginning of the study and between the active treatment periods. Eligible subjects were not current Non-Steroidal Anti-Inflammatory Drug (NSAID) users, had controlled hypertension, and could receive stable doses of up to 2 different classes of antihypertensive drugs.

NicOx is developing naproxcinod in late phase 3 clinical studies, which are designed to demonstrate that it is safe, well tolerated and effective for treating the signs and symptoms of osteoarthritis, in addition to having no detrimental effect on blood pressure, in contrast to traditional NSAIDs and COX-2 inhibitors. The results of the third phase 3 trial for naproxcinod (the 303 study) are expected before the end of the year and the filing of a New Drug Application (NDA) for naproxcinod with the U.S. Food and Drug Administration (FDA) is projected for mid-2009.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting N
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

679

GOOD

Page: 1 2 3

Related biology technology :

1. NicOx Reports Results for the First Three Quarters of 2008
2. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
3. NicOx Announces Departure of Damian Marron for CEO Position
4. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
5. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
6. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
7. NicOx Opens U.S. Headquarters in New Jersey
8. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
9. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
10. New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
11. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014  CSSi ( www.CSSiEnroll.com ), the leader ... industry, is pleased to announce its participation in ... October.  President Chris Trizna will be ... Clinical Trials New England conference sponsored by Arena ... annual Site Solutions Summit sponsored by the Society ...
(Date:10/2/2014)... and BRIDGEWATER, N.J. , ... , a leader in synthetic biology, and ... drug manufacturer by volume in the U.S., today ... Collaboration (ECC) for a target active pharmaceutical ingredient ... goal of the collaboration is to develop a ...
(Date:10/1/2014)... What: , Cambridge Semantics, the leading provider ... technology, today announced its participation in the 2014 Big ... Data solutions provide semantic linkage and meaning to Big ... and manage diverse data. Ben Szekely, vice president and ... a “life sciences data lake” and an approach for ...
(Date:10/1/2014)... 1, 2014  Discovery Laboratories, Inc. (Nasdaq: DSCO) ... a Phase II Small Business Innovation Research Grant ... the National Institute of Allergy and Infectious Diseases ... to support the development of the Company,s aerosolized ... to mitigate acute and chronic/late-phase radiation-induced lung injury. ...
Breaking Biology Technology:Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 2Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 3Intrexon and Amneal Expand Relationship with Second Product Collaboration 2Intrexon and Amneal Expand Relationship with Second Product Collaboration 3Cambridge Semantics to Present ‘A Useful Approach to Big Data’ at 2014 Big Data Leaders Forum 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... , , , ... (Nasdaq: NBIX ) announced today that the Company will report ... Wednesday, July 29, 2009. Neurocrine will then host a ... a Company update Thursday morning, July 30, 2009 at 8:30 a.m. Eastern ...
... ASHLAND, Mass., July 23 MatTek Corp., today announced ... EpiDerm(TM) SIT non-animal alternative test method for determining the human ... , , This 20 minute ... (JoVE). Titled, "An In Vitro Skin Irritation Test (SIT) ...
... , , , ... to Severe Post-Operative Pain , , ... (Pink Sheets: QRXPY; ASX: QRX) announced today the initiation of a ... of MoxDuo(TM) IV (intravenous morphine and oxycodone) versus IV morphine alone ...
Cached Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results 2Video of EpiDerm Skin Irritation Test (SIT) Method Now Available 2QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy 2QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy 3
(Date:10/1/2014)... Case Western Reserve University researchers hope to take a ... for an aggressive form of breast cancer in leafy ... about administering the vaccine either by eating the salad ... Nicole Steinmetz, assistant professor of biomedical engineering at Case ... project. , The Susan G. Komen breast cancer organization ...
(Date:9/30/2014)... burning is published today in the first authoritative scientific ... tensions on both sides of the grouse moor management ... on the Ecohydrology of River basins) project has shown ... to support red grouse populations for gun sports, has ... physical properties, river water chemistry and river ecology. , ...
(Date:9/30/2014)... 2014--Sea monkeys have captured the popular attention of both ... life cycle -- sold as dehydrated eggs, these tiny ... more than a tank of salt water. , ... other zooplankton, brine shrimp vertically migrate in large groups ... the surface at night and retreating deeper during the ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3Grouse moor burning causes widespread environmental changes 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2
... SAN FRANCISCO -- The northernmost mummified forest ever found in ... global cooling. Researchers believe the trees -- buried by ... ago -- will help them predict how today,s Arctic will ... more mummified forests could emerge across North America as Arctic ...
... Two scientists at Scripps Institution of Oceanography at UC ... mysterious flashes of dazzling bioluminescent light produced by a ... of Scripps Oceanography (Wilson is now at the Australian ... a small marine snail typically found in tight clusters ...
... the little things that count, and that certainly holds ... enough to allow ions or molecules of a certain size ... nanochannels that mimic the capabilities of transmembrane proteins are highly ... been difficult to make individual artificial channels of this size ...
Cached Biology News:Ancient forest emerges mummified from the Arctic 2Ancient forest emerges mummified from the Arctic 3Scripps scientists see the light in bizarre bioluminescent snail 2Tiny channels carry big information 2Tiny channels carry big information 3
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: